Arrhythmias and heart failure

Cardiology Clinics

Volumn 32, Issue 1, 2014, Pages 125-133

  Saltzman, Heath E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Heart failure; Ventricular tachyarrhythmia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; ENCAINIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBOPAMINE; LIDOCAINE; METOPROLOL; MEXILETINE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TRANDOLAPRIL; VALSARTAN;

BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIC CARDIOMYOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SECONDARY PREVENTION; SUDDEN CARDIAC DEATH; SYSTOLIC HEART FAILURE; TACHYCARDIA INDUCED CARDIOMYOPATHY; TORSADE DES POINTES;

ARRHYTHMIA; ATRIAL FIBRILLATION; HEART FAILURE; VENTRICULAR TACHYARRHYTHMIA;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; HEART FAILURE; HUMANS; TACHYCARDIA, VENTRICULAR;

EID: 84888302446     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.09.005     Document Type: Review

References (82)

1. National Heart, Lung, and Blood Institute NHLBI fiscal year 2009 factbook 2009, National Institutes of Health, Bethesda (MD).
2. American Heart Association Heart Disease, Stroke Statistics Writing Group Executive summary: heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(4):459-463.
3. Friberg J., Buch P., Scharling H., et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003, 14:666-672.
4. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
5. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994, 271(11):840-844.
6. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003, 107:2920-2925.
7. Lloyd-Jones D., Larson M., Leip E., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068.
8. Middlekauff H.R., Stevenson W.G., Stevenson L.W. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991, 84:40-48.
9. Carson P.E., Johnson G.R., Dunkman W.B., et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87(Suppl 6):VI102-VI110.
10. Mahoney P., Kimmel S., DeNofrio D., et al. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999, 83:1544-1547.
11. Senni M., Tribouilloy C.M., Rodeheffer R.J., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998, 98:2282-2289.
12. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT): the Department of Veterans Affairs CHF-STAT investigators. Circulation 1998, 98:2574-2579.
13. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
14. Deedwania P.C., Lardizabal J.A. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010, 123(3):198-204.
15. Corell P., Gustafsson F., Schou M., et al. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007, 9:258-265.
16. Leonard J.J., Shaver J., Thompson M. Left atrial transport function. Trans Am Clin Climatol Assoc 1981, 92:133-141.
17. Rahimtoola S.H., Ehsani A., Sinno M.Z., et al. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med 1975, 59(5):686-694. Atrial Fibrillation in Heart Failure 1997.
18. Pozzoli M., Cioffi G., Traversi E., et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. JAm Coll Cardiol 1998, 32(1):197-204.
19. Gosselink A.T., Crijns H.J., van den Berg M.P., et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994, 72:161-166.
20. Pedersen O.D., Bagger H., Køber L., TRACE Study Group, et al. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarction. Int J Cardiol 2005, 100:65-71.
21. Crijns H.J., Tjeerdsma G., de Kam P.J., et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000, 21(15):1238-1245.
22. Ahmed A., Perry G.J. Incident atrial fibrillation and mortality in older adults with heart failure. Eur J Heart Fail 2005, 7:1118-1121.
23. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 2005, 26(13):1303-1308.
24. Raymond R.J., Lee A.J., Messineo F.C., et al. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J 1998, 136(3):435-442.
25. Shite J., Yokota Y., Yokoyama M. Heterogeneity and time course of improvement in cardiac function after cardioversion of chronic atrial fibrillation: assessment of serial echocardiographic indices. Br Heart J 1993, 70(2):154-159.
26. Pardaens K., Van Cleemput J., Vanhaecke J., et al. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997, 78:564-568.
27. Clark D.M., Plumb V.J., Epstein A.E., et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. JAm Coll Cardiol 1997, 30(4):1039-1045.
28. Zupan I., Rakovec P., Budihna N., et al. Tachycardia induced cardiomyopathy in dogs: relation between chronic supraventricular and chronic ventricular tachycardia. Int J Cardiol 1996, 56:75-81.
29. Armstrong P.W., Stopps T.P., Ford S.E., et al. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986, 74:1075-1084.
30. Wilson J.R., Douglas P., Hickey W.F., et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987, 75:857-867.
31. Zipes D.P. Atrial fibrillation: a tachycardia-induced atrial cardiomyopathy. Circulation 1997, 95:562-564.
32. Van Gelder I.C., Crijns H.J., Blanksma P.K., et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993, 72:560-566.
33. Shinbane J.S., Wood M.A., Jensen D.N., et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. JAm Coll Cardiol 1997, 29(4):709-715.
34. Byrne M.J., Raman J.S., Alferness C.A., et al. An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. JCard Fail 2002, 8(2):108-115.
35. Nerheim P., Birger-Botkin S., Piracha L., et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004, 110:247-252.
36. Solti F., Vecsey T., Kékesi V., et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989, 23:882-886.
37. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87-95.
38. Guerra J.M., Everett T.H., Lee K.W., et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006, 114:110-118.
39. Lee K.W., Everett T.H., Rahmutula D., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006, 114:1703-1712.
40. Wyse D.G., Waldo A.L., DiMarco J.P., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, et al. Acomparison of rate control and rhythm control in patients with atrial fibrillation. NEngl J Med 2002, 347:1825-1833. 59.
41. Van Gelder I.C., Hagens V.E., Bosker H.A., Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group, et al. Acomparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. NEngl J Med 2002, 347:1834-1840.
42. Opolski G., Torbicki A., Kosior D.A., Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest 2004, 126:476-486.
43. Al-Khatib S.M., Shaw L.K., Lee K.L., et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure?. Am J Cardiol 2004, 94:797-800.
44. Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation: pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000, 356:1789-1794.
45. Talajic M., Khairy P., Levesque S., et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. JAm Coll Cardiol 2010, 55(17):1796-1802.
46. Van Gelder I.C., Groenveld H.F., Crijns H.J., et al. Lenient versus strict rate control in patients with atrial fibrillation. NEngl J Med 2010, 362(15):1363-1373.
47. Echt D.S., Liebson P.R., Mitchell L.B., the CAST Investigators, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial. NEngl J Med 1991, 324:781-788.
48. Køber L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. NEngl J Med 2008, 358(25):2678-2687.
49. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian trial of atrial fibrillation. NEngl J Med 2000, 342:913-920.
50. Weinfeld M.S., Drazner M.H., Stevenson W.G., et al. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. JHeart Lung Transplant 2000, 19:638-643.
51. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigation of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation 2001, 104:292-296.
52. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. JAm Coll Cardiol 2008, 51:802-809.
53. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
54. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331-336.
55. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926-2931.
56. Nasr I.A., Bouzamondo A., Hulot J.S., et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28:457-462.
57. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003, 92:1379-1383.
58. Fauchier L., Pierre B., de Labriolle A., et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a metaanalysis of randomized controlled trials. JAm Coll Cardiol 2008, 51:828-835.
59. Wood M.A., Brown-Mahoney C., Kay G.N., et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation. Circulation 2000, 101:1138-1144.
60. Ganesan A.N., Brooks A.G., Roberts-Thomson K.C., et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: a systematic review. JAm Coll Cardiol 2012, 59(8):719-726.
61. Dagres N., Varounis C., Gaspar T., et al. Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. JCard Fail 2011, 17(11):964-970.
62. Kannel W.B., Wilson P.W., D'Agostino R.B., et al. Sudden coronary death in women. Am Heart J 1998, 136(2):205-212.
63. Mosterd A., Cost B., Hoes A.W., et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001, 22(15):1318-1327.
64. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. NEngl J Med 1991, 325(5):293-302.
65. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. NEngl J Med 1992, 327(10):685-691.
66. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
67. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. NEngl J Med 1992, 327(10):669-677.
68. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial investigators. NEngl J Med 1996, 335(26):1933-1940.
69. Moss A.J., Fadl Y., Zareba W., et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol 2001, 88(5):516-520.
70. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346(12):877-883.
71. Greenberg H., Case R.B., Moss A.J., et al. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). JAm Coll Cardiol 2004, 43(8):1459-1465.
72. Buxton A.E., Lee K.L., Fisher J.D., et al. Arandomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. NEngl J Med 1999, 341(25):1882-1890.
73. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352(3):225-237.
74. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. NEngl J Med 2004, 350(21):2140-2150.
75. Theuns D.A., Smith T., Hunink M.G., et al. Effectiveness of prophylactic implantation of cardioverter defibrillators without cardiac resynchronization therapy in patients with ischaemic or nonischaemic heart disease: a systematic review and meta-analysis. Europace 2010, 12(11):1564-1570.
76. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344:1651-1658.
77. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001, 357:1385-1390.
78. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
79. Piccini J.P., Berger J.S., O'Conner C.M., et al. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomised controlled trials. Eur Heart J 2009, 30:1245-1253.
80. Connolly S.J., Dorian P., Roberts R.S., et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. JAMA 2006, 295:165-171.
81. Pacifico A., Hohnloser S.H., Williams J.H., et al. Prevention of implantable defibrillator shocks by treatment with sotalol. D,L-Sotalol Implantable Cardioverter-Defibrillator Study group. NEngl J Med 1999, 340:1855-1862.
82. Waldo A.L., Camm A.J., Deruyter H., et al. Effect ofd-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral D-sotalol. Lancet 1996, 348:7-12.